Whistleblower Takes Takeda FCA Case To Supreme Court

Law360, Los Angeles (May 21, 2013, 4:38 PM EDT) -- A Takeda Pharmaceuticals North America Inc. sales leader has asked the U.S. Supreme Court to revive his whistleblower suit accusing the company of defrauding Medicare by overbilling for stomach acid drug prescriptions, arguing that it meets False Claims Act qualifications.

Noah Nathan said in a petition filed on May 10 that four circuit courts had ruled that an FCA qui tam suit only needs to detail a scheme to submit false claims and present sufficient evidence that the claims were submitted, which his suit did....
To view the full article, register now.